Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism

madman

Super Moderator
ABSTRACT

Purpose


Although several reviews have evaluated the use of PDE5 inhibitors (PDE5i) for treating erectile dysfunction (ED), their specific use in middle-aged and old patients has not been fully evaluated. Given that elderly patients with ED often have a complex combination of systemic and sexual health risk factors, the safety and efficacy of PDE5i in such a context are hereby reviewed.


Materials and methods

A thorough examination of existing literature has been conducted on PubMed.


Results

PDE5i has good safety and efficacy, but the situation is more complex for patients with hypogonadism than those with normal testosterone levels, with reduced responsiveness to PDE5i. In this case, combination therapy with testosterone is recommended, safe and effective.


Conclusions

Eliminating or reducing reversible risk factors and controlling or slowing the development of irreversible factors is an important foundation for using PDE5i to treat ED in all patients, especially middle-aged and elderly ones.




*The safety and efficacy of PDE5 inhibitors in middle-aged and elderly patients with ED and without hypogonadism


*Reversible risk factors


*Concomitant and underlying risks

-Metabolic disorders
-Endocrine diseases
-Cardiovascular disease
-Urological risk factors
-After radical prostatectomy
-Infertility
-Loss of control over erection and ejaculation (LCEE)
-Psychological and partner relationship factors



*The safety and efficacy of PDE5 inhibitors in middle-aged and elderly patients with ED and hypogonadism




Conclusion


As research continues to deepen, we are increasingly aware that sexual health is a barometer of overall human health, which enables us to apply a holistic (systemic) approach to thoroughly understand the risk factors of ED. The efficacy of PDE5i for ED in elderly patients also depends on the management of the complex interplay involving different general and sexual health risk factors that most elderly patients often exhibit. In the presence of various systemic and sexual health risk factors, PDE5i has shown good safety, with common adverse reactions including headache, flushing, and muscle pain. Compared with individuals with normal testosterone levels, patients with hypogonadism have a more multifaceted situation and reduced responsiveness to PDE5i. Combination therapy with testosterone can effectively improve responsiveness, and adverse events are not significantly increased. In summary, eliminating reversible risk factors and slowing or controlling the development of irreversible factors are important foundations for PDE5i therapy.
 

Attachments

Figure 1. The common systemic and sexual health risk factors related to ED and the differences in responsiveness to PDE5i between ED patients with and without hypogonadism. ED: erectile dysfunction; PDE5-is: phosphodiesterase type 5 inhibitors; RP: radical prostatectomy; PPRF: psychological and partner relationship factors; LUTS: lower urinary tract symptoms; DM: diabetes mellitus. “ …” represents the classification of risk factors of ED. “.-.-.” represents treatment. “——” represents a causal relationship
Screenshot (31758).webp

Screenshot (31759).webp
 
*The efficacy of PDE5i for ED in elderly patients also depends on the management of the complex interplay involving different general and sexual health risk factors that most elderly patients often exhibit.

*Compared with individuals with normal testosterone levels, patients with hypogonadism have a more multifaceted situation and reduced responsiveness to PDE5i. Combination therapy with testosterone can effectively improve responsiveness, and adverse events are not significantly increased.
 
*In summary, eliminating reversible risk factors and slowing or controlling the development of irreversible factors are important foundations for PDE5i therapy.
 

hCG Mixing Calculator

HCG Mixing Protocol Calculator

TRT Hormone Predictor Widget

TRT Hormone Predictor

Predict estradiol, DHT, and free testosterone levels based on total testosterone

⚠️ Medical Disclaimer

This tool provides predictions based on statistical models and should NOT replace professional medical advice. Always consult with your healthcare provider before making any changes to your TRT protocol.

ℹ️ Input Parameters

Normal range: 300-1000 ng/dL

Predicted Hormone Levels

Enter your total testosterone value to see predictions

Results will appear here after calculation

Understanding Your Hormones

Estradiol (E2)

A form of estrogen produced from testosterone. Important for bone health, mood, and libido. Too high can cause side effects; too low can affect well-being.

DHT

Dihydrotestosterone is a potent androgen derived from testosterone. Affects hair growth, prostate health, and masculinization effects.

Free Testosterone

The biologically active form of testosterone not bound to proteins. Directly available for cellular uptake and biological effects.

Scientific Reference

Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, LaValley MP, Mazer NA, Bhasin S. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010 Aug;95(8):3955-64.

DOI: 10.1210/jc.2010-0102 | PMID: 20534765 | PMCID: PMC2913038

Beyond Testosterone Podcast

Online statistics

Members online
2
Guests online
194
Total visitors
196

Latest posts

Back
Top